Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.70 |
| ▸ | SRC | P12931 | 5/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.59 |
| ▸ | AURKA | O14965 | 4/20 | 0.54 |
| ▸ | LCK | P06239 | 4/20 | 0.54 |
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | TEK | Q02763 | 4/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748110 | 0.91 | KDR (0.72) | KDRSRCTGFBR1AURKALCK | |
| SCHEMBL2749249 | 0.91 | KDR (0.69) | KDRSRCTGFBR1AURKALCK | |
| SCHEMBL2747740 | 0.89 | KDR (0.75) | KDRSRCTGFBR1AURKALCK | |
| SCHEMBL2747336 | 0.87 | KDR (0.85) | KDRAURKALCKMETTEK | |
| SCHEMBL4548748 | 0.87 | KDR (0.73) | KDRSRCTGFBR1AURKALCK | |
| SCHEMBL2748514 | 0.86 | KDR (0.72) | KDRSRCTGFBR1AURKALCK | |
| SCHEMBL2747074 | 0.85 | KDR (0.67) | KDRSRCTGFBR1AURKALCK | |
| SCHEMBL2746830 | 0.85 | KDR (0.70) | KDRSRCTGFBR1AURKALCK | |
| SCHEMBL2749314 | 0.85 | KDR (0.70) | KDRAURKALCKMETTEK | |
| SCHEMBL4549002 | 0.85 | KDR (0.87) | KDRSRCAURKALCKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885SRC 405/4885TGFBR1 1035/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885SRC 405/4885TGFBR1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.